Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Dual Blockade of the Renin-Angiotensin System in Glomerular Diseases

Author(s): Antonietta Gigante* and Rosario Cianci

Volume 21, Issue 2, 2023

Published on: 01 March, 2023

Page: [75 - 77] Pages: 3

DOI: 10.2174/1570161121666230220123207

« Previous Next »
[1]
Saran R, Li Y, Robinson B, et al. US renal data system 2015 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis 2016; 67(3): A7-8.
[http://dx.doi.org/10.1053/j.ajkd.2015.12.014] [PMID: 26925525]
[2]
Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021; 100(4): S1-S276.
[http://dx.doi.org/10.1016/j.kint.2021.05.021]
[3]
Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med 2019; 86(9): 601-7.
[http://dx.doi.org/10.3949/ccjm.86a.18024] [PMID: 31498767]
[4]
Mei M, Zhou Z, Zhang Q, Chen Y, Zhao H, Shen B. Dual blockade of the renin-angiotensin system: A strategy that should be reconsidered in cardiorenal diseases? Nephron J 2021; 145(2): 99-106.
[http://dx.doi.org/10.1159/000513119] [PMID: 33550292]
[5]
Zhao M, Wang R, Yu Y, et al. Efficacy and safety of angiotensin-converting enzyme inhibitor in combination with angiotensin-receptor blocker in chronic kidney disease based on dose: A systematic review and meta-analysis. Front Pharmacol 2021; 12: 638611.
[http://dx.doi.org/10.3389/fphar.2021.638611] [PMID: 34025408]
[6]
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547-59.
[http://dx.doi.org/10.1056/NEJMoa0801317] [PMID: 18378520]
[7]
Esteras R, Perez-Gomez MV, Rodriguez-Osorio L, Ortiz A, Fernandez-Fernandez B. Combination use of medicines from two classes of renin-angiotensin system blocking agents: Risk of hyperkalemia, hypotension, and impaired renal function. Ther Adv Drug Saf 2015; 6(4): 166-76.
[http://dx.doi.org/10.1177/2042098615589905] [PMID: 26301070]
[8]
Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367(23): 2204-13.
[http://dx.doi.org/10.1056/NEJMoa1208799] [PMID: 23121378]
[9]
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369(20): 1892-903.
[http://dx.doi.org/10.1056/NEJMoa1303154] [PMID: 24206457]
[10]
Sprenger-Mähr H, Zitt E, Lhotta K. Acute kidney injury treated with dialysis outside the intensive care unit: A retrospective observational single-center study. PLoS One 2016; 11(9): e0163512.
[http://dx.doi.org/10.1371/journal.pone.0163512] [PMID: 27673681]
[11]
Joannidis M, Hoste E. Angiotensin inhibition in patients with acute kidney injury: Dr. Jekyll or Mr. Hyde? Intensive Care Med 2018; 44(7): 1159-61.
[http://dx.doi.org/10.1007/s00134-018-5223-8] [PMID: 29860704]
[12]
Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52(3): 475-85.
[http://dx.doi.org/10.1053/j.ajkd.2008.03.008] [PMID: 18468748]
[13]
Lennartz DP, Seikrit C, Wied S, et al. Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy. J Nephrol 2020; 33(6): 1231-9.
[http://dx.doi.org/10.1007/s40620-020-00836-8] [PMID: 32856272]
[14]
Teo YN, Ting AZH, Teo YH, et al. Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors and combined SGLT1/2 inhibitors on cardiovascular, metabolic, renal, and safety outcomes in patients with diabetes: A network meta-analysis of 111 randomized controlled trials. Am J Cardiovasc Drugs 2022; 22(3): 299-323.
[http://dx.doi.org/10.1007/s40256-022-00528-7] [PMID: 35316484]
[15]
Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100(1): 215-24.
[http://dx.doi.org/10.1016/j.kint.2021.03.033] [PMID: 33878338]

Rights & Permissions Print Cite
Article Metrics
19
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy